Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

1,020 enrolled

Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06757634 2026-02-05

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

Phase 3 Recruiting

674 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

196 enrolled

Breast

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

Phase 1/2 Recruiting

435 enrolled

Breast

Breast Neoplasms

NCT04563507 2025-12-15

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Phase 2 Recruiting

102 enrolled

Breast

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06062498 2025-10-20

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Phase 2 Recruiting

174 enrolled

Breast

Breast Neoplasms

NCT04567420 2025-10-16

DARE

Phase 2 Recruiting

70 enrolled

Breast

Breast Neoplasms

NCT05216432 2025-09-22

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

Phase 1 Recruiting

930 enrolled

Breast

Breast Neoplasms

NCT06856200 2025-03-04

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

Phase NA Recruiting

36 enrolled

Breast

Advanced HR - Positive, HER2 - Negative Breast Cancer

NCT06805812 2025-02-03

PALMARES-2

Recruiting

3,500 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT04985266 2024-12-05

TRAK-ER

Phase 2 Recruiting

1,100 enrolled

Breast

ER+ Breast Cancer

NCT06307249 2024-03-12

PTST_PALBEVA

Phase 1 Recruiting

50 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Inflammation, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms

NCT05766410 2023-03-16

ORACLE-RIPA

Phase 2 Recruiting

60 enrolled

Breast

Breast Neoplasms

Clinical Trials

Study of INCB123667 in Subjects With Advanced Solid Tumors

EvoPAR-BR01

PALAVY

CYCAD-1

PAveMenT

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

SIRI

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

reaINAVO

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Morpheus-panBC

CAPItello-292

PIKALO-1

FourLight-3

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

ELEVATE

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Study of AVZO-021 in Patients With Advanced Solid Tumors

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

DARE

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

PALMARES-2

TRAK-ER

PTST_PALBEVA

ORACLE-RIPA